TuHURA Biosciences — Third Quarter 2026 Earnings Summary

TuHURA Biosciences reported third-quarter 2026 financial results showing $1.9 million in cash and cash equivalents alongside $3.7 million in research and development expenses. The company announced preliminary data from its IFx-2.0 and Keytruda study in metastatic Merkel cell carcinoma patients, demonstrating major objective tumor responses in the first three subjects. TuHURA also received FDA clearance to initiate a Phase 1b trial for its VISTA-inhibiting antibody TBS-2025 in relapsed or refractory acute myeloid leukemia and secured new patents for its VISTA inhibitor and Delta Opioid Receptor technology. To support these initiatives, the company accessed $5.6 million in non-dilutive financing from its Parkview credit facility during the quarter.